

University of Groningen

## Prospective Study on Individualized Dose Adjustment of Tolvaptan Based on Urinary Osmolality in Patients With ADPKD

Geertsema, Paul; Soonawala, Darius; Gansevoort, Ron T.; Meijer, Esther

*Published in:*  
Kidney International Reports

*DOI:*  
[10.1016/j.ekir.2024.10.042](https://doi.org/10.1016/j.ekir.2024.10.042)

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*  
Publisher's PDF, also known as Version of record

*Publication date:*  
2025

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Geertsema, P., Soonawala, D., Gansevoort, R. T., & Meijer, E. (2025). Prospective Study on Individualized Dose Adjustment of Tolvaptan Based on Urinary Osmolality in Patients With ADPKD. *Kidney International Reports*, 10(1), 271. <https://doi.org/10.1016/j.ekir.2024.10.042>

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*

# Prospective Study on Individualized Dose Adjustment of Tolvaptan Based on Urinary Osmolality in Patients With ADPKD



**To the Editor:** In their editorial, Dahl *et al.*<sup>1</sup> write that the study by Roca Oporto *et al.*<sup>2</sup> offers reassurance that most patients with autosomal dominant polycystic kidney disease can remain on the starting dose of tolvaptan (45/15 mg once daily) without requiring dose escalation, if urine osmolality stays below 200 mOsm/kg in 24-hour urine. The study by Roca Oporto *et al.* deals with an important subject and is well-reported. However, we think it is too early to advocate that dose escalation may not be necessary.

As the authors state, the conclusion is based on a limited set of uncontrolled data ( $n = 40$ ). In comparison, the efficacy of tolvaptan is based on randomized controlled trials in nearly 900 patients on active treatment.<sup>3</sup> Our main concern is that efficacy needs to be based on controlled data with sufficient power to show a clinically relevant benefit. As the authors mention in their study, the slow decline in estimated glomerular filtration rate after starting treatment may reflect regression to the mean instead of a treatment effect.

Furthermore, urine osmolality may not accurately reflect vasopressin blockade, particularly in patients with more severe disease (chronic kidney disease stage G3 and higher). These patients may exhibit urine osmolality <200 mOsm/kg and elevated copeptin levels even without tolvaptan because of impaired urine concentrating ability.<sup>4</sup> Thus, basing dosing solely on urine osmolality may not indicate true vasopressin receptor blockade, although such patients may particularly benefit from treatment. Roca Oporto's study does not report changes in vasopressin or copeptin levels during treatment.

Finally, in most patients, the most significant reduction in urine osmolality and increase in 24-hour urine volume occurs at the lowest tolvaptan dose, with minimal additional changes from subsequent increase

in dose.<sup>5</sup> Thus, up-titration is unlikely to increase the incidence of aquaretic adverse events but may reduce treatment efficacy on disease progression.

We therefore agree with the original study authors in calling for randomized trials to determine whether dosing tolvaptan based on urine osmolality is as effective as titrating to 90/30 mg once daily based on tolerability.

1. Dahl NK, Torres VE. What is the appropriate dose of tolvaptan in ADPKD? *Kidney Int Rep.* 2024;9:737–739. <https://doi.org/10.1016/j.ekir.2024.01.049>
2. Roca Oporto FJ, Andrades Gómez C, Montilla Cosano G, Aguilera AL, Rocha JL. Prospective study on individualized dose adjustment of tolvaptan based on urinary osmolality in patients with ADPKD. *Kidney Int Rep.* 2024;9:1031–1039. <https://doi.org/10.1016/j.ekir.2024.01.020>
3. Torres VE, Chapman AB, Devuyt O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. *N Engl J Med.* 2012;367:2407–2418. <https://doi.org/10.1056/NEJMoa1205511>
4. Casteleijn NF, Zitteema D, Bakker SJL, et al. Urine and plasma osmolality in patients with autosomal dominant polycystic kidney disease: reliable indicators of vasopressin activity and disease prognosis? *Am J Nephrol.* 2015;41:248–256. <https://doi.org/10.1159/000382081>
5. Todorova P, Arjune S, Hendrix C, et al. Interaction between determinants governing urine volume in patients with ADPKD on tolvaptan and its impact on quality of life. *Kidney Int Rep.* 2023;8:1616–1626. <https://doi.org/10.1016/j.ekir.2023.05.011>

Paul Geertsema<sup>1</sup>, Darius Soonawala<sup>2</sup>  
Ron T. Gansevoort<sup>1</sup> and Esther Meijer<sup>1</sup>

<sup>1</sup>Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands and; and <sup>2</sup>Department of Internal Medicine, HagaZiekenhuis, The Hague, The Netherlands

**Correspondence:** Esther Meijer, Department of Nephrology, Expertise Center for Polycystic Diseases, University Medical Center Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands. E-mail: [esther.meijer@umcg.nl](mailto:esther.meijer@umcg.nl)

**Received 21 October 2024; accepted 28 October 2024; published online 12 November 2024**

*Kidney Int Rep* (2025) **10**, 271; <https://doi.org/10.1016/j.ekir.2024.10.042>

© 2024 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).